Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study

Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus

(2019) Shereen Oon et al.   ANNALS OF THE RHEUMATIC DISEASES

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:post-hocanalysis of the Phase IIb MUSE trial of anifrolumab

(2018) Eric F Morand et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort

(2018) Michelle Petri et al.   Arthritis & Rheumatology

Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus

(2018) Joan T. Merrill et al.   Arthritis & Rheumatology

Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999–2014)

(2017) April M Jorge et al.   RHEUMATOLOGY

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA

(2017) Désirée van der Heijde et al.   RHEUMATOLOGY

Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study

(2017) Vera Golder et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Remission in systemic lupus erythematosus: durable remission is rare

(2016) Theresa R Wilhelm et al.   ANNALS OF THE RHEUMATIC DISEASES

A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)

(2016) Ronald van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Remission in SLE — are we there yet?

(2016) Eric F. Morand   Nature Reviews Rheumatology

Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus

(2016) Michel W. P. Tsang-A-Sjoe et al.   RHEUMATOLOGY

Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period

(2016) Carmen V. Medina-Quiñones et al.   ARTHRITIS CARE & RESEARCH

Remission in SLE: closing in on the target

(2015) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Prolonged remission in Caucasian patients with SLE: prevalence and outcomes

(2015) Margherita Zen et al.   ANNALS OF THE RHEUMATIC DISEASES

Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)

(2015) Kate Franklyn et al.   ANNALS OF THE RHEUMATIC DISEASES

Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus

(2015) D C Salazar-Camarena et al.   LUPUS

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

(2014) David Isenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

(2014) Ian N Bruce et al.   ANNALS OF THE RHEUMATIC DISEASES

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force

(2014) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

The need to define treatment goals for systemic lupus erythematosus

(2014) Kate Franklyn et al.   Nature Reviews Rheumatology

The BAFF/APRIL system in SLE pathogenesis

(2014) Fabien B. Vincent et al.   Nature Reviews Rheumatology

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus

(2013) FB Vincent et al.   LUPUS

Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort

(2013) E. M. McCarthy et al.   RHEUMATOLOGY

Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort

(2011) R. Lopez et al.   RHEUMATOLOGY

Assessment of a lupus nephritis cohort over a 30-year period

(2011) S. C. Croca et al.   RHEUMATOLOGY

Raised serum level of APRIL in patients with systemic lupus erythematosus: Correlations with disease activity indices

(2010) M. Hegazy et al.   CLINICAL IMMUNOLOGY

Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus

(2010) J. Nossent et al.   LUPUS

Novel evidence-based systemic lupus erythematosus responder index

(2009) Richard A. Furie et al.   ARTHRITIS AND RHEUMATISM